NovaBridge Biosciences (NBP) Operating Income (2019 - 2025)

NovaBridge Biosciences (NBP) has reported Operating Income for 5 consecutive years, with -$72.9 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Operating Income fell 445.21% year-over-year to -$72.9 million; the TTM figure through Dec 2025 stood at -$94.3 million (down 83.31% YoY), while the FY2025 annual figure was -$94.3 million, down 83.31% from the prior year.
• Operating Income retreated to -$72.9 million in Q4 2025 per NBP's latest filing, from -$9.0 million in the prior quarter.
• Across five years, Operating Income topped out at -$5.3 million in Q1 2025 and bottomed at -$72.9 million in Q4 2025.
• Historically, Operating Income has averaged -$18.9 million across 3 years, with a median of -$12.0 million in 2023.
• Annual changes were most pronounced in 2024 — Operating Income jumped 66.12% — and 2025, when it slumped 445.21%.
• NovaBridge Biosciences' Operating Income stood at -$39.5 million in 2023, then surged by 66.12% to -$13.4 million in 2024, then plunged by 445.21% to -$72.9 million in 2025.
• Business Quant data shows NBP's Operating Income at -$72.9 million in Q4 2025, -$9.0 million in Q3 2025, and -$7.1 million in Q2 2025.